Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Dapagliflozin Tablets, 5 mg and 10 mg. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD) Farxiga Tablets, 5 mg and 10 mg, of AstraZeneca AB (AstraZeneca). Dapagliflozin Tablets are indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Dapagliflozin Tablets have an estimated market size of $1.7 billion for twelve months ending December 2018 according to IQVIA.
Alembic now has a total of 99 ANDA approvals (88 final approvals and 11 tentative approvals) from USFDA.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1525.00 |
Dr. Reddys Lab | 5942.65 |
Cipla | 1345.35 |
Zydus Lifesciences | 925.95 |
Lupin | 1547.05 |
View more.. |